Solasia Pharma K.K. reported consolidated earnings results for the three months ended March 31, 2021. For the period, the company reported revenue of JPY 91 million as compared to JPY 156 million for the same period last year. Operating loss was JPY 642 million as compared to loss of JPY 534 million for the same period last year. Loss attributable to owners of parent was JPY 656 million as compared to loss of JPY 531 million for the same period last year. Basic loss per share were JPY 5.22 as compared to loss per share of JPY 4.57 for the same period last year. Loss was JPY 656 million as compared to loss of JPY 531 million for the same period last year.